# OnCo record mt-601 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mt-601/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mt-601" ;
  schema:name "MT-601"@en ;
  schema:description "MT-601 is an experimental autologous multi-antigen recognizing T cell therapy, not genetically modified from Marker Therapeutics, in phase 1 trials for relapsed lymphoma and pancreatic cancer."@en ;
  schema:url <https://onco.cc/drugs/mt-601/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://markertherapeutics.com/>, <https://markertherapeutics.com/>, <https://markertherapeutics.com/>, <https://clinicaltrials.gov/api/v2/studies/NCT05798897>, <https://clinicaltrials.gov/search?intr=MT-601> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Autologous multi-antigen recognizing (MAR) T cell therapy, not genetically modified" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:targets <https://onco.cc/targets/birc5/>, <https://onco.cc/targets/prame/>, <https://onco.cc/targets/ctag1b/>, <https://onco.cc/targets/mage-a4/>, <https://onco.cc/targets/ssx2/>, <https://onco.cc/targets/wt1/> ;
  onco:companies <https://onco.cc/companies/marker-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct05798897/>, <https://onco.cc/trials/nct06549751/> .